Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Affimed NV's average Accounts Receivable for the
three
months ended in Sep. 2024 was $5.60 Mil. Affimed NV's Revenue for the
three
months ended in Sep. 2024 was $0.17 Mil.
Hence, Affimed NV's Days Sales Outstanding for the
three
months ended in Sep. 2024 was 2,969.87.
The historical rank and industry rank for Affimed NV's Days Sales Outstanding or its related term are showing as below:
AFMDQ's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.98 * Ranked among companies with meaningful Days Sales Outstanding only.
Affimed NV's Days Sales Outstanding
increased
from Sep. 2023 (107.72) to Sep. 2024 (2,969.87).
Affimed NV (OTCPK:AFMDQ) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Affimed NV Days Sales Outstanding Related Terms
Affimed NV Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Affimed NV's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFMDQ vs SYRS, BTAX, TRVN: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Affimed NV's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affimed NV Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Affimed NV's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Affimed NV's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 2,969.87 mean?
Affimed NV (AFMDQ) has a Days Sales Outstanding of 2,969.87 as of Sep. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Affimed NV and its competitors.
Is Affimed NV's Days Sales Outstanding too high?
Affimed NV's current Days Sales Outstanding is 2,969.87. The Biotechnology industry median Days Sales Outstanding is 68.98. Affimed NV's value of 2,969.87 is 4205.4% above this industry median. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's Days Sales Outstanding compare to SYRS and BTAX?
Affimed NV's Days Sales Outstanding of 2,969.87 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.98. Affimed NV's value of 2,969.87 is 4205.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Affimed NV's current Days Sales Outstanding of 2,969.87 is 4205.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Affimed NV and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Affimed NV's current Days Sales Outstanding is 2,969.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current Days Sales Outstanding of 2,969.87. The current Days Sales Outstanding is 2,969.87 and 4205.4% above the Biotechnology industry median of 68.98. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current Days Sales Outstanding is 2,969.87 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score
Get the complete analysis for AFMDQ
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AFMDQ has been successfully added to your 
